ANTI-INTERLEUKIN 6 (IL-6) RECEPTOR ANTIBODY SUPPRESSES CASTLEMAN'S DISEASE LIKE SYMPTOMS EMERGED IN IL-6 TRANSGENIC MICE-Reference-Cited by-同舟云学术

ANTI-INTERLEUKIN 6 (IL-6) RECEPTOR ANTIBODY SUPPRESSES CASTLEMAN'S DISEASE LIKE SYMPTOMS EMERGED IN IL-6 TRANSGENIC MICE

Published:2002-12 Issue:6 Volume:20 Page:304-311
ISSN:1043-4666
Container-title:Cytokine
language:en
Short-container-title:Cytokine

Author:

Katsume Asao,Saito Hiroyuki,Yamada Yoshiki,Yorozu Keigo,Ueda Otoya,Akamatsu Ken-Ichi,Nishimoto Norihiro,Kishimoto Tadamitsu,Yoshizaki Kazuyuki,Ohsugi Yoshiyuki

Publisher

Elsevier BV

Subject

Molecular Biology,Hematology,Biochemistry,Immunology,Immunology and Allergy

Reference35 articles.

1. Interleukin-6 in biology and medicine;Akira;Advances in Immunol,1993

2. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease;Yoshizaki;Blood,1989

3. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice;Brant;J Clin Invest,1990

4. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis;Hirano;Eur J Immunol,1988

5. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis;Houssiau;Arthritis Rheum,1988

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-Interleukin-6 receptor antibody;Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology;2024-06-20

2. Biomarkers and Signaling Pathways Implicated in the Pathogenesis of Idiopathic Multicentric Castleman Disease/Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly (TAFRO) Syndrome;Biomedicines;2024-05-21

3. Involvement of Inflammatory Cytokines, Renal NaPi-IIa Cotransporter, and TRAIL Induced-Apoptosis in Experimental Malaria-Associated Acute Kidney Injury;Pathogens;2024-05-01

4. Animal Models of Anemia;Animal Models In Experimental Medicine;2024-02-01

5. Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances;Blood Reviews;2023-12